Background
clotting factor concentrates (CFCs) in approximately 30% of people with severe (defined as less than 1 international unit (IU) dL⁻¹ baseline clotting factor activity) hemophilia A (FVIII deficiency) and 2% to 5% of those with severe hemophilia B (FIX deficiency) (Iorio 2010a) .
In an analysis of the UK Haemophilia Centre Doctors' Organisation database, the cumulative risk of inhibitor formation was 16% and 36% at five years and 75 years of age (respectively) for the 6078 males with hemophilia A and 6% and 8% (respectively) for the 1172 males with hemophilia B (Darby 2004) . The rate of inhibitor formation is dependent on the residual or baseline circulating FVIII or FIX level, being greatest in those people with severe disease (Hay 1998) . Among people with non-severe disease, those with certain mutations, particularly in the A2 and C2 domains of the F8 gene, are more likely to develop inhibitory antibodies.
Development of inhibitors is a complex process, but likely includes factors related to the individual being treated, the environment and the treatment provided. Patient-related or genetically determined factors include ethnicity, race, the severity of the hemophilia, hemophilia causing mutation, major histocompatibility class, and immunogenotype (Astermark 2010a) . Environmental or non-genetic factors are ones perceived by the immune system as danger signals (Matzinger 1994; Matzinger 2012 ) and may include the reason for the first infusion at a young age and the intensity of treatment (Astermark 2010b ).
Description of the intervention
Once the diagnosis of an inhibitor is made, treatment options include the management of acute bleeding, prevention of bleeding, and immune tolerance induction (ITI), the latter being the primary treatment option (Collins 2013) . One randomized prospective trial of ITI in children with favorable risk factors has been completed (Hay 2012) . Although 70% of participants had a complete response to ITI, six of 37 participants relapsed after a median of 9.5 months. Those in whom ITI failed or who relapsed after successful ITI, along with those in whom ITI was not attempted or those on ITI but still with bleeding, remain at risk for bleeding and hence are candidates for prophylaxis with a bypassing agent.
Recombinant activated FVII (rFVIIa) and plasma-derived activated prothrombin complex concentrate (APCC) are currently the only two bypassing agents available for use in people with hemophilia with inhibitors. Two randomized trials of acute bleeding management with bypassing agents have been completed, one with rFVIIa (Young 2008) and one with APCC (Astermark 2007 ) but neither involved a comparison of the prophylactic use of the two drugs. These trials were reviewed in 2010 and superiority of one treatment over the other in terms of hemostatic control or thrombosis risk could not be demonstrated in participants with acute bleeding (Iorio 2010b) . Similarly, several nonrandomized studies failed to demonstrate superiority of one agent over the other (Chuansumrit 2000; Kavakli 2006; Lusher 1998; Pruthi 2007; Santagostino 2006; Seremetis 1994; Shapiro 1998 ).
Frequent bleeding, especially joint bleeding, is a common disease manifestation in people with hemophilia and inhibitors and impacts overall health, joint health, and quality of life (Scalone 2006) . Prophylaxis is the use of treatment on a regular basis to prevent or reduce bleeding episodes. The choice of prophylactic infusion requires the medication to be effective for bleeding management. Therefore, prophylaxis in people with hemophilia with inhibitors that do not respond to routine factor concentrates must rely on the use of bypassing agents. In people without inhibitors, prophylaxis is regarded as standard of care and is associated with a reduction in musculoskeletal disease burden and with a good quality of life . However, experience with prophylaxis is limited in people with inhibitors.
In 2013, Collins recommended that prophylaxis with a bypassing agent should be considered in children with inhibitors after the first hemarthrosis in an effort to prevent joint damage and in older people with recurrent bleeding (Collins 2013 ) . Regarding the choice of bypassing agent, it was recommended that this decision be individualized based on prior response to treatment, logistics of administration and cost. In October 2013, the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation recommended that prophylaxis with bypassing agents should be considered in people with inhibitors (MASAC 2013) . No specific guidelines were provided to guide clinicians who wished to prescribe prophylaxis.
The optimal treatment for people with hemophilia without inhibitors is the prophylactic administration of factor VIII (hemophilia A) or factor IX (hemophilia B) concentrates . The development of neutralizing antibodies makes treatment of bleeding with CFCs more difficult and when the concentration of the antibody is above a certain level (≥ 5 Bethesda units dL⁻¹ (BU)), replacement therapy is no longer effective (Berntorp 2006) . In these cases with high titres of antibody, treatment with bypassing agents, either rFVIIa or APCC, is necessary to control acute bleeding (Shapiro 2003 ).
Prevention of bleeding or prophylaxis in cases with high titres of antibody requires use of rFVIIa or APCC.
How the intervention might work
The development of anti-factor VIII or anti-factor IX antibodies makes the administration of substitution therapy with factor VIII or IX (respectively) ineffective. Bypassing agents are treatments that are able to activate the coagulation cascade independently of factor VIII and IX; thus they are unaffected by the presence of factor VIII or factor IX inhibitors. Bypassing agents, including rFVIIa and APCC, have different mechanisms of action by which they drive coagulation. It is known that rFVIIa activates factor Xa on an activated platelet surface or when, it is bound to tissue factor, it can directly activate thrombin. Alternatively, APCC mainly acts by providing factors IX and X which are able to bypass the need for FVIII to drive thrombin generation (Hedner 2000) .
Prophylaxis with bypassing agents may prevent bleeding in people with hemophilia with inhibitors and specifically reduce overall bleeding rates and joint bleeding rates without excess thrombotic and infectious risks. Ideally, prophylaxis with bypassing agents in people with inhibitors will ensure long-term joint protection, in the way that the prophylactic administration of factor VIII and IX does in people without inhibitors.
Why it is important to do this review
The rationale for this review is that prophylaxis with bypassing agents may improve the quality of life for people with hemophilia A or B with inhibitors and reduce the economic burden of treatment. This information may help to inform and guide clinicians in decision making when managing people with congenital hemophilia and inhibitors.
Objectives
To assess the effects of bypassing agent prophylaxis to prevent bleeding in people with hemophilia A or B and inhibitors.
Methods
Criteria for considering studies for this review
Types of studies
Randomized controlled studies and quasi-randomized controlled studies (cross-over or parallel design).
Types of participants
Males of any age with severe congenital hemophilia A or B complicated by high-responding inhibitors to FVIII or FIX, respectively, requiring a bypassing agent as prophylaxis to control or prevent bleeding.
Types of interventions
Prophylaxis, at any dose, any dosing frequency, and any regimen, of rFVIIa or APCC for preventing bleeding versus each other or no prophylaxis.
Types of outcome measures

Primary outcomes
Overall bleeding events (per month), as defined by study authors 1.
Secondary outcomes
Annualised bleeding rate 1.
Target joint bleeding rate 2.
Annualised joint bleeding rate (AJBR) 3.
Quality of life (QoL) (generic and specific validated scales including EQ-5D, Haem-A-QoL, Haemo-QoL) 4.
Safety of the bypassing agents including adverse events, serious adverse events, or thromboembolic events 5.
Cost and resource utilization when comparing prophylaxis to on-demand treatment regimens, including overall drug 6. utilization
Search methods for identification of studies
There were no restrictions regarding language or publication status.
Electronic searches
We identified relevant studies from the Cystic Fibrosis and Genetic Disorders Group's Coagulopathies Trials Register using the terms: (Factor VIII Inhibitors) OR (factor inhibitors). 
Searching other resources
The bibliographic references of retrieved studies were reviewed for additional references to be included in this review.
Data collection and analysis
Selection of studies
Two review authors independently reviewed the abstracts from the identified articles to select those that were potentially 0179 Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors eligible to be included in the review. The authors retrieved the full text reports of studies that were deemed potentially relevant and linked together multiple reports of the same study. The authors independently examined the full text of the studies for compliance with the eligibility criteria; and if necessary contacted the study investigators to determine study eligibility. The authors resolved any disagreements on study inclusion by discussion in order to reach a consensus.
Data extraction and management
A pair of authors (CC, SJN and MS) independently reviewed the identified articles and extracted data on the following (a third author arbitrated any differences).
Inclusion criteria for the study 1.
Location and timeframe of the study 2.
Participant number and demographics 3.
Study methods 4.
Study design 5.
Type, characteristics and duration of the intervention and control groups if applicable 6.
Outcome measures and description 7.
Information on limitations or bias (or both) 8.
Assessment of risk of bias in included studies
A pair of authors (CC, SJN and MS) independently assessed the risk of bias of the included studies. The risk of bias was assessed using Cochrane's tool for assessing the risk of bias according to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a) . For each study, the risk of bias was noted as being either 'high risk', 'low risk', or 'unclear risk' for the following criteria.
Sequence generation 1.
Allocation concealment 2.
Blinding of participant and personnel 3.
Blinding of outcome assessment 4.
Incomplete outcome data 5.
Selected outcome reporting 6.
Other issues 7.
Measures of treatment effect
For the primary outcome, overall bleeding events were represented as a mean number of bleeding events per month. Secondary outcomes of target joint bleeding events and annualised joint bleeding events were represented as a mean number of bleeding events per month. We analyzed the data as continuous data, and reported mean differences (MD) with the corresponding 95% confidence intervals (CIs).
For safety outcomes, i.e. adverse events related to treatment, the effect was presented as the proportion of males presenting the event, and a risk ratio (RR). We calculated a pooled estimate of the treatment effect for each outcome using the pooled RR and 95% CIs.
With respect to health-related quality of life (HRQoL), the mean and standard deviation (SD) of scores from scales were presented. We calculated the mean change from baseline for each group or the mean post-intervention values and SD for each group. We converted standard errors (SE) to SDs. We produced a pooled estimate of treatment effect by calculating the MD and 95% CIs. If economic data are reported in updates of this review, we will analyse these data in the same way.
If for a future update, continuous scores measure the same outcome but in a variety of ways (e.g. different scales to measure knowledge or quality of life), we plan to standardize the outcomes to a uniform scale using the standardized MD (SMD).
Where studies reported multiple measures for the same outcome, the review authors considered absolute changes in the measure in the context of comparable data being available for each participant before and after the intervention (i.e. change from baseline).The authors recorded continuous data, such as joint score change, as either mean change from baseline for each group or mean post-treatment values (if change from baseline was not reported) and SD for each group.
Unit of analysis issues
No cluster-randomized studies were identified. If cluster-randomized studies are identified for updates of the review, we will check these studies for unit of analysis errors and perform analysis based on the advice given in chapter 16 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011b ).
When conducting a meta-analysis combining results from cross-over studies, we used the methods recommended by Elbourne (Elbourne 2002 ). We extracted (or calculated) MDs and SEs adjusted for the paired design of cross-over studies. If this had not been possible, we would have considered whether data were presented by treatment period and include only first-period data in the analysis. If neither of these options were possible, we would have included data from cross-over studies narratively in the review.
We included one cross-over study in the review . For the outcome of overall bleeding events, we were able to extract individual participant data from a graph and calculate a MD and adjusted SE. We were also able to estimate that the correlation between treatment arms was around 0.4 from these data. Therefore, we have used this correlation estimate to adjust estimates of SE for other continuous outcomes measured in this study.
Dealing with missing data 0179 Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors If reports were incomplete, we attempted to contact the original investigators in an effort to obtain the necessary data or information. Where the original investigators could not provide additional information, we examined the proportion and distribution of missing data (e.g. proportion of missing outcome data, demographic data, missing information regarding study design methods etc.). We also considered, where possible, whether data were likely to be missing at random or not and whether the missing data were likely to have had an impact on the results of the study. We judged the risk of bias due to incomplete outcome data accordingly and performed sensitivity analyses, excluding studies with large proportions of missing data, if appropriate.
Assessment of heterogeneity
We assessed heterogeneity through visual examination of the combined data presented in the forest plots, and by considering the I² statistic together with Chi² values (significance level P < 0.1) (Deeks 2011) . The I² statistic reflects the likelihood that variation of results across studies are due to heterogeneity rather than by chance, and is interpreted as follows: 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
We intended to assess publication bias by constructing, then visually inspecting, the funnel plot (where a minimum of 10 studies could be included), and investigated outcome reporting bias by comparing the methods and results sections of the published papers.
Data synthesis
Where meta-analysis could be conducted, we employed a fixed-effect model in the first instance. For future updates, when moderate or higher heterogeneity is identified (I² of around 30% or higher), a random-effects model will be employed. For dichotomous outcomes (adverse events related to treatment), we employed the Mantel-Haenszel method of meta-analysis and present pooled RRs and 95% CIs. For continuous outcomes (overall bleeding events, annualised bleeding rate, target joint bleeding events, annualised bleeding events, HRQoL, economic data, joint score change), we employed the inverse variance method of meta-analysis and present pooled MD or SMD (as appropriate, see Measures of treatment effect) and 95% CIs.
Subgroup analysis and investigation of heterogeneity
If we had identified moderate or higher heterogeneity (I² of around 30% or higher), we intended to investigate this by subgroup analyses based on: diagnosis (e.g. hemophilia A or B); 1.
age of the participants (boys or adult males). 2.
Sensitivity analysis
We intended to explore the impact of including studies with high levels of missing data on the overall treatment effect, if appropriate.
Summary of findings and quality of the evidence (GRADE)
In a post hoc change from protocol, we have presented a summary of findings tables for each comparison in the review (Summary of findings table 1; Summary of findings table 2).
The following outcomes were reported in the tables (chosen based on relevance to clinicians and consumers): overall bleeding events; annualised bleeding rate; target joint bleeding rate; AJBR; quality of life; safety of the bypassing agents.
We determined the quality of the evidence using the GRADE approach; and downgraded evidence in the presence of a high risk of bias in at least one study, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results, high probability of publication bias. We downgraded evidence by one level if they considered the limitation to be serious and by two levels if very serious (Balshem 2011; Guyatt 2008) .
Results
Description of studies We identified 96 citations from the database searches. We identified a further 89 references from searches of trial registries. Of the total 185 references, we removed three duplicates. After we reviewed the remaining titles and abstracts, 151 were discarded as not being relevant and we retrieved the full-text references (where possible) of nine studies (31 references). Of these, four unique studies (reported in 26 references) were eligible randomized controlled studies and were included in the review Konkle 2007; Ljung 2013 ) . We excluded four studies (NCT02622321; NCT02795767; NCT02847637; NCT03020160) and classified one study as awaiting further assessment (NCT01105546).
Included studies See Characteristics of included studies.
Four studies are included in the review Konkle 2007; Ljung 2013 ).
The Antunes study was a multicenter, parallel, randomized controlled study conducted in 17 centers . Participants were enrolled if they were hemophilia A or B with a history of high-titre inhibitor (> 5 BU/mL) or low-titre inhibitor (≤ 5 BU/mL) with refractory to increased dosing of factor replacement therapy. A total of 17 participants were randomized to prophylaxis group and 19 were randomized to the on-demand therapy group. Prophylaxis regimen was nanofiltered FVIII inhibitor bypassing activity (FEIBA NF) 85 +/-15 units/kg bolus infusion every other day. Participants who were in the ondemand therapy group received FEIBA NF administration when they experienced a bleeding episode, dosing depended on type of bleeding. The study lasted for 12 months. The primary outcome was annualised bleeding rate. Secondary outcomes were AJBR, overall bleeding events, target joint bleeding events, occurrence of new target joints, hemostatic efficacy, total FEIBA NF utilization, safety and QoL.
The Konkle study was a multicenter, parallel, randomized controlled study conducted in 20 centers (Konkle 2007) . Participants were enrolled if they had severe hemophilia A or B with a high inhibitor titre (> 2 BU/mL), required treatment of bleeds with a bypassing agent and had had at least four bleeds requiring hemostatic drug treatment within the previous month prior to enrolling. There were three study periods (pre-prophylaxis, prophylaxis and post-prophylaxis). Each period was for three consecutive months. Eleven participants were randomized to rFVIIa 270 μg/kg once daily and 11 were randomized to rVFIIa 90 μg/kg once daily. The primary outcome was the number of bleeds per month. Secondary outcomes were site-specific bleeding rates, safety, HRQoL and orthopedic joint scores.
The Leissinger study was a multicenter, cross-over study conducted in 16 centers . Eligible participants were males with severe hemophilia A and a history of high-titre inhibitor (> 5 BU/mL), who were older than two years of age, being treated with bypassing agents and had six or more episodes of bleeding requiring treatment in the six months prior to study enrollment. Prophylaxis regimen was anti-inhibitor coagulant complex (AICC)-FEIBA at a target dose of 85 (+/-15%) units/kg. During the on-demand therapy period, participants received FEIBA at a dose of 85 (+/-15%) units/kg if they experienced bleeding episodes. A total of 17 participants were randomized to prophylaxis first (six months of prophylaxis, followed by a three-month washout period and six months of an on-demand period). A total of 17 participants were randomized to on-demand therapy first (six months of on-demand therapy, followed by three months of washout period and six months of prophylaxis). The primary outcome was total bleeding events (prophylaxis versus on-demand periods). Secondary outcomes were the number of joint bleeds, the number of target joint bleeds, HRQoL and safety.
The Ljung study was a multicenter, parallel study conducted in 19 centers (Ljung 2013) . Eligible participants had hemophilia A or B with high titre inhibitor (≥ 5 BU/mL, frequent bleeds, age 12 to 65 years), had at least two bleeding episodes within the last month or 12 bleeding episodes within the last six months prior to enrolling. There were three study periods (three months of observation, followed by three months of prophylaxis and one month of observation). The prophylaxis regimen was 40K glycoPEGylated recombinant FVIIa bypassing agent (N7-GP) administered at target doses of 25 μg/kg, 100 μg/kg and 200 μg/kg intravenously every second day. During the on-demand period, participants received rFVIIa for the treatment of bleeding episodes. The primary outcome was a reduction in the annualised bleeding rate (prophylaxis versus on-demand therapy periods). Secondary outcomes were the number of specific bleeds (stratified by sites) and causes of bleeding.
Excluded studies
We identified four studies which were excluded from the review (NCT02622321, NCT02795767, NCT02847637, NCT03020160) as the study drug was neither rFVIIa or APCC.
Studies awaiting assessment
We identified one study which we are currently awaiting further information on, once obtained, we will assess this for eligibility (NCT01105546).
Risk of bias in included studies
See Figure 2 and 
Allocation (selection bias)
The Antunes study used centralised stratified, block randomization , the Konkle study used centralised computer-generated randomization (Konkle 2007 ) and the Leissinger study conducted the randomization and treatment allocation by using centralized call center (telephone randomization) . Risk of selection bias was judged as 'low risk' of bias for these three studies. The Ljung study described that the participants were randomized and stratified by age (Ljung 2013) . There was no further information regarding random sequence generation and allocation concealment; the risk of bias for this study was judged as 'unclear'.
Blinding (performance bias and detection bias)
Two studies were open-label and there was no information regarding the blinding of outcome assessors; therefore the risk of bias was judged as 'high risk' ). The Konkle and Ljung studies described the blinding procedure as providing an equal volume of trial drug to be injected in both groups (Konkle 2007; Ljung 2013 ). There was no information regarding blinding of the outcome assessors; the risk of bias was judged as 'low risk' for the latter studies.
Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors
Incomplete outcome data (attrition bias)
The Antunes study reported that two participants withdrew from the on-demand group and one from the prophylaxis group . The Ljung study reported that three participants withdrew during the study period (one from the 100 μg/kg group and one from the 200 μg/kg group) (Ljung 2013 ). There were no withdrawals during the study period in the Konkle study (Konkle 2007) . All participants were included in an intention-to-treat analysis. The participants were well balanced across groups. The risk of bias was judged to be 'low risk' for these three studies. The Leissinger study reported that one participant withdrew consent before receiving the study medication and a further seven did not complete the study; the risk of bias was judged as 'high risk' for this study Selective reporting (reporting bias)
All of the studies clearly specified primary and secondary outcomes. The data on all outcomes were reported. There was no evidence of selective reporting, therefore, the risk of bias was judged to be 'low risk' for all four studies.
Other potential sources of bias All four studies were deemed to be at 'low risk' of bias from other source of bias.
Effects of interventions
Two comparisons were made in this review, prophylaxis compared to on-demand therapy and low-dose compared to highdose therapy.
Prophylaxis compared to on-demand therapy Two studies recruiting 70 participants contributed to this comparison . Both studies compared prophylaxis to on-demand therapy with FEIBA (AICC or NF).
Primary outcome 1. Overall bleeding rates (per month)
One study reported on the bleeding rate per month (over a six-month period) on prophylaxis and on-demand therapy . At six months, prophylaxis with bypassing agent (FEIBA) significantly reduced mean overall bleeding rates, MD -7.27 (95% CI -9.92 to -4.62) (low quality evidence) (Analysis 1.1) and the mean number of overall bleeding per month, MD -1.10 (95% CI -1.54 to -0.66) compared with those who are on-demand group (Analysis 1.2).
Secondary outcomes 1. Annualised bleeding rates
One study reported on annualised bleeding rates; however, data were presented as median values and cannot be entered into analysis . The median annualised bleeding rate was significantly lower among those who were allocated to prophylaxis as compared to on-demand treatment (7.9 versus 28.7) (moderate quality evidence).
Joint bleeding rates
One study reported mean number of hemarthrosis . At six months, prophylaxis with bypassing agent (FEIBA) significantly reduced mean number of hemarthrosis, MD -6.60 (95% CI -9.32 to -3.88) when compared to on-demand treatment (low quality evidence) (Analysis 1.3). Mean number of joint hemorrhages was significantly lower among those who were on prophylaxis, MD -0.90 (95% CI -1.36 to -0.44) when compared to those with on-demand therapy (Analysis 1.4).
AJBR
One study reported on annualised bleeding rates; however, data were presented as median values and cannot be entered into analysis . The median AJBR was significantly lower among those who were allocated to prophylaxis as compared to on-demand treatment (6.0 versus 22.9) (moderate-quality evidence).
Quality of life
Two studies reported outcome regarding to HRQoL (low-quality evidence) . The Antunes study evaluated HRQoL using the Haem-A-QoL, Haemo-QoL, EQ-5D, and general pain visual analog scale (VAS) at six and 12 months ). Leissinger assessed HRQoL using the EQ-5D questionnaire and the Short-Form (SF)-36 Health survey .
After 12 months of study, mean change from baseline of Haem-A-QoL score was not significantly different but in favour of prophylaxis as compared with on-demand treatment, MD 3.40 (95% CI, -5.53 to 12.33) (Analysis 1.5). Mean change from baseline of EQ-5D scores were not significantly different but in favour prophylaxis, measuring at six months, MD 0.09 (95% CI -0.09 to 0.27) and 12 months, MD 0.07 (95% CI -0.13 to 0.27) (Analysis 1.6). Mean change from baseline of EQ-5D VAS was not significantly different but in favour prophylaxis, measuring at six months, MD 4.11 (95% CI, -3.66 to 11.88) and 12 months, MD 9.90 (95% CI, -5.93 to 25.73) (Analysis 1.7). Mean change from baseline of EQ-5D utility score were not statistically different between prophylaxis and on-demand group, MD 0.00 (95% CI -0.12 to 0.12) (Analysis 1.8). The mean change from baseline of SF36-physical summary score was not significantly different comparing between prophylaxis and on-demand treatment at six months, MD 2.90 (95% CI -1.53 to 7.33) (Analysis 1.17). Likewise, the mean change from baseline of SF36-mental summary score was not significantly different comparing between prophylaxis and on-demand treatment at six months, MD
Safety of the bypassing agents
Two studies reported on the safety of the bypassing agents (low quality evidence) ). Antunes reported 36 (28.8%) of treated participants in two groups experienced serious adverse effects . No study reported thromboembolic events or major safety issues. Leissinger reported that one participant had an allergic reaction to the study drug during prophylaxis and three participants had events related to central venous access during prophylaxis and on-demand therapy (Leissinger 2011).
Cost and resource utilization
Neither study reported this outcome High-dose compared to low-dose prophylaxis therapy Two studies recruiting 46 participants contributed to this comparison (Konkle 2007; Ljung 2013) . Both compared doses of rFVIIa; Konkle compared 270 μg/kg to 90 μg/kg and Ljung compared three doses of 200 μg/kg, 100 μg/kg and 25 μg/kg (Konkle 2007; Ljung 2013 One study reported the overall bleeding rates comparing high-dose (270 μg/kg) versus low-dose (90 μg/kg) rFVIIa (Konkle 2007) . High-dose rFVIIa reduced the mean number of bleeds per month when compared to low-dose rFVIIa, but the difference between the groups was not statistically significant, MD -0.82 (95% CI -2.27 to 0.63) (moderate quality evidence) (Analysis 2.1).
Ljung reported the mean annualised bleeding rate per month, comparing three doses of rFVIIa (200 μg/kg, 100 μg/kg and 25 μg/kg) (Ljung 2013) . The mean annualised bleeding rates per month were reduced during prophylaxis as compared to the on-demand treatment period for all three doses of rFVIIa. The bleeding rate could not be analysed between the groups due to the inadequate outcome reports.
Secondary outcomes 1. Annualised bleeding rates
Ljung reported annualised bleeding among those who received three different doses of rFVIIa (Ljung 2013) . As compared to on-demand treatment period, the annualised bleeding rate during prophylaxis were reduced by 36%, 45% and 52% in participants who received rFVIIa 200 μg/kg, 100 μg/kg and 25 μg/kg, respectively. The bleeding rate could not be analysed between the groups due to the inadequate outcome reports.
Joint bleeding rate
One study reported target joint bleeding rates comparing high-dose (270 μg/kg) versus low-dose (90 μg/kg) rFVIIa (Konkle 2007) . At three months, high-dose rFVIIa reduced mean joint bleeding rates when compared to low-dose rFVIIa but the difference between the groups was not statistically significant, MD -3.20 (95% CI -7.23 to 0.83) (moderate quality evidence) (Analysis 2.2).
AJBR
Neither study reported this outcome (Konkle 2007; Ljung 2013 ).
Quality of life
Safety of the bypassing agents
Two studies reported adverse events comparing high-dose versus low-dose rFVIIa (Ljung 2013; Konkle 2007 ). There was no statistical difference of the risk of adverse events between doses, RR 1.00 (95% CI 0.57 to 1.76) for 200 μg/kg compared to 100 μg/kg, RR 1.50 (95% CI 0.67 to 3.34) for 200 μg/kg compared to 25 μg/kg, RR 1.50 (95% CI 0.67 to 3.34) for 100 μg/kg compared to 25 μg/kg and RR 0.89 (95% CI 0.56 to 1.40) for 270 μg/kg compared to 90 μg/kg (moderate-quality evidence) (Analysis 2.3).
One study reported serious adverse events comparing high-dose versus low-dose rFVIIa (Konkle 2007) . Four participants who received high-dose rFVIIa (270 μg/kg) reported serious adverse events compared to no participants who received low-dose (90 μg/kg). However, this difference between groups was not statistically significant, RR 9.00 (95% CI 0.54 to 149.50) (Analysis 2.4).
Cost and resource utilization
Neither study reported this outcome (Konkle 2007 Two studies compared prophylaxis versus on-demand treatment and two studies compared high to low doses of bypassing agents for prophylaxis (Konkle 2007; Ljung 2013) . The main findings of this Cochrane Review and meta-analysis in people with hemophilia with inhibitors suggested that prophylaxis with bypassing agents reduces overall bleeding rates and joint bleeding rates as compared to on-demand treatment. No statistically significant differences in change from baseline for HRQoL were found and this review did not conclusively rule out benefit or harm of high-dose compared with low-dose rFVIIa.
Overall completeness and applicability of evidence All of the included studies enrolled people with hemophilia A or hemophilia B with inhibitors. Two studies compared prophylaxis with on-demand treatment . However, the remaining two studies did not include participants who were given on-demand treatment as a control (Konkle 2007; Ljung 2013) . The prophylactic durations ranged from three months to 12 months. The data were presented differently (e.g. crude bleeding rate, annualised bleeding rate or bleeding per month) and reported in mean or median. Consequently, meta-analyses were prevented in some cases. Two studies evaluated HRQoL; however, the tools used in these studies varied . Consequently, a pooled analysis could not be performed for the majority of HRQoL domains. Although we observed statistically significant differences of the clinical outcomes regarding to the reduction of overall bleeding rates and joint bleeding rates in those who were allocated to prophylaxis as compared to on-demand treatment, the clinical relevance of this finding warrant further prospective studies with a greater number of participants and a longer duration of follow-up.
Although the studies included in this review were conducted as multicenter, multinational studies; bypassing agents as a prophylaxis in people with hemophilia with inhibitors are not widely used in countries where the resources are limited. Hence, the applicability of this evidence to certain groups of people with hemophilia A or B is limited.
Quality of the evidence
When comparing between prophylaxis versus on-demand treatment, the quality of the evidence was moderate for outcomes relating to annualised bleeding rates; we downgraded the evidence due to the imprecision of limited data from one or two small studies. Other outcomes (bleeding rates, HRQoL and safety) provided low quality evidence for this comparison; in addition to imprecision, evidence was also downgraded due to incomplete outcome data with up to 24% of participants excluded from one cross-over study.
When comparing high-dose to low-dose rFVIIa, the quality of evidence was moderate for overall bleeding rates, target joint bleeding rate and safety of bypassing agents; we downgraded evidence due to imprecision of limited data from one or two small studies. Other outcomes were not reported for this comparison.
Potential biases in the review process
We performed extensive searches for this Cochrane Review. The methodology regarding study selection, data extraction, risk of bias assessment and analyses were rigorously conducted. We contacted the corresponding authors for clarification on data; however, there were some missing reported outcomes regarding overall bleeding rate, joint bleeding rate and healthrelated outcomes. In addition, the small number of included studies in this review precluded us from conducting subgroup analyses.
Agreements and disagreements with other studies or reviews
Valentino conducted a systematic review of six observational studies, involving 34 hemophilia people with inhibitors who were treated with FEIBA for prophylaxis (Valentino 2010) . The median prophylactic dose was 78.5 unit per kg. There was 63.9% reduction in overall bleeding events and 73% reduction in annual joint bleeding.
Authors' conclusions Implications for practice
The evidence suggests that prophylaxis with bypassing agent may be effective in people with hemophilia A or B with inhibitors for the reduction of overall bleeding rates and joint bleeding rates (low to moderate quality evidence). There is insufficient evidence to show that prophylaxis does affect health-related quality of life (HRQoL) as compared to on-demand treatment (low quality evidence). There is lack of evidence of superiority of one agent over the other as well as the dosage regimen.
Implications for research
The small sample sizes and substantial attrition rates of the included studies limited the precision of the effect estimates. Larger prospective studies are warranted in order to evaluate the efficacy of prophylaxis compared to on-demand treatment and high-dose versus low-dose regimen of bypassing agents. In addition, outcome measures (such as bleeding event and HRQoL) were non-uniformly reported. Consequently, it is difficult to compare the results across the studies and to perform meta-analyses. Hemophilia-specific tools for assessing HRQoL may be more informative and uniform. The hemophilia research community needs to develop a consensus on measuring and reporting outcomes in hemophilia-related literature.
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Differences between protocol and review
In a post hoc change from protocol, two summary of findings tables (one for each comparison) have been added to the review. Outcomes were selected based on relevance to clinicians and consumers
Published notes
Sarah J Nolan (author of the protocol) is now Sarah J Nevitt.
Characteristics of studies
Characteristics of included studies Methods Multicenter parallel randomized study conducted in 17 centres in Bulgaria, Russia, Croatia, Poland, Romania, USA, Japan and Brazil Participants 36 males (prophylaxis (n = 17) or on-demand therapy (n = 19))
Inclusion criteria: hemophilia A or B with documented history of high-titre inhibitor (> 5 BU/mL) or low-titre inhibitor (≤ 5 BU/mL) refractory to increased dosing of either FVIII or FIX for at least 12 months; were ≥ 4 and ≤ 65 years of age; were currently being treated on demand with bypassing agents; had ≥ 12 bleeding episodes in the previous 12 months; and a negative HIV status, or if positive, with a stable CD4 count Exclusion criteria: symptomatic liver disease; had platelet count < 100,000 per μL; were currently receiving ITI or prophylaxis; needed elective surgery; needed alphainterferon or protease inhibitor use; or had previous thromboembolic events Konkle 2007 Methods Multicenter randomized parallel study conducted across 20 sites in Argentina, Brazil, Bulgaria, the Philippines, Poland, Romania, Russia, South Africa, Spain, Turkey and USA Participants 22 participants (rFVIIa 270 μg/kg (n = 11) and rFVIIa 90 μg/kg (n = 11))
Inclusion criteria: males with severe congenital hemophilia A or B with a high documented history of inhibitor titre (with an inhibitor titre > 2 BU/mL in the preceding 12 months), a requirement for current treatment of bleeds with bypassing agents, and at least four bleeds requiring hemostatic drug treatment (except dental bleeds and bruises) within the previous month.
Exclusion criteria: prophylaxis with any hemostatic drug within the last 3 months, ITI within the last month, known pseudotumours, platelet count < 50,000 per μL, advanced atherosclerotic disease, and congenital or acquired coagulation disorders other than hemophilia A or B
Interventions
There were 3 phases of 3-month study period (pre-prophylaxis, prophylaxis and postprophylaxis periods).
Prophylaxis with high dose: activated rFVIIa 270 μg/kg once daily, slow bolus intravenously over a period of 2 minutes Prophylaxis with low dose: rFVIIa 90 μg/kg once daily Outcomes Primary outcome: number of bleeds per month comparing between during the prophylaxis period and pre-prophylaxis period Secondary outcomes: number of bleeds per month comparing between postprophylaxis period and prophylaxis period, site specific bleeding rates, safety, HRQoL, orthopedic joint scores Notes On-demand treatments of acute/breakthrough bleeds were continued as normal practice throughout the study. 38 participants were originally recruited for the study, 37 entered the pre-treatment observation period but 15 were withdrawn Inclusion criteria: severe hemophilia A and a history of a factor VIII inhibitor titre exceeding 5 BU, older than 2 years old, being treated with bypassing agents and had 6 or more episodes of bleeding requiring treatment in the 6 months before the study Exclusion criteria: receiving immune tolerance therapy, regular prophylaxis with any hemostatic agent, symptomatic liver disease, platelet count of less than 100,000 per μL, planned elective surgery within 12 months, used an investigational product within 1 month of study enrolment, planned to begin treatment with interferon or protease inhibitor Interventions Prophylaxis: AICC (FEIBA) administration at a target dose of 85 units/kg (+/-15%) on 3 non-consecutive days weekly
On demand: AICC at a target dose of 85 units/kg (+/-15%) for bleeding episode Duration of treatment: 6 months of prophylaxis, 3 months of washout period and 6 months of on-demand therapy (prophylaxis first), 6 months of on-demand therapy, 3 months of washout period and 6 months of prophylaxis (on-demand therapy first) The mean total number of bleeding events in the prophylaxis group was 7.27 lower than the ondemand group (9.92 lower to 4.62 lower).
Not estimable (see comment)
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(1 study) 1 ⊕⊕⊝⊝ low 2, 3 Corresponding risk (mean difference between groups) was estimated taking account of the cross-over design of the study. Assumed risk in the on-demand group cannot be directly calculated.
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(1 study) NA
Results showed reduction of overall bleeding rates for all 3 groups during prophylaxis as compared to on-demand period.
(Data could not be entered into analysis as SDs not presented.)
Target joint bleeding rate
Follow-up: 3 months
The mean number of joint bleeds per month in the low-dose group was 4.7
The mean number of bleeds per month in the high-dose group was 3.20 lower than the lowdose group (7.23 lower to 0.83 higher). 
